Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (827.77%) | (661.72%) | (338.31%) | (139.55%) |
+8 more TTM periods Free account |
|
| (278.04%) | (242.20%) | (177.82%) | (100.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(336.66%) | (338.76%) | (213.70%) | (118.71%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(16.81) | (12.28) | (55.68) | (110.55) | |
Free Cash Flow |
(8.94) | (6.53) | (5.40) | (4.43) | |
Capital Expenditures |
(0.62) | — | (0.57) | — | |
| Other line items | |||||
Cash ROIC |
(70.91%) | (55.86%) | (32.54%) | (48.94%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
519.79% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
198.09% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Operating CF/Net income |
0.58 | 0.50 | 0.39 | 0.89 | |
Depreciation/Fixed assets |
0.06 | 0.34 | 0.18 | 0.00 | |
Capex/Depreciation |
(25.09) | 0.00 | (79.71) | 0.00 | |
Revenue per Share |
3.89 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.65) | (12.28) | (49.76) | (110.55) | |
Capex per Share |
(1.16) | 0.00 | (5.92) | 0.00 | |
Capex to Sales |
0.30 | — | 0.00 | — |
Columns are period end dates